ClinicalTrials.gg

Program

XTR003

A development code. Also written as “Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging”.

Its studies are mostly in Heart Failure · Myocardial Ischemia · Coronary Artery Disease, led by Sinotau Pharmaceutical Group.

Furthest: phase 2, since Dec 25, 20223 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinotau Pharmaceutical Group31 open or runningphase 2since Dec 25, 2022Nov 23, 2021Dec 31, 2026phase 2 · NCT07443696

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 23, 2021First study: phase 1 study in Coronary Artery DiseaseFirst studyNCT05136391 · 10 enrolled · China
  2. Dec 25, 2022Phase 2 study in Myocardial IschemiaNCT05885854 · 51 enrolled · China
  3. Dec 24, 2025Phase 2 study in Heart FailureNCT07443696 · 40 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Heart FailureNCT07443696

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07443696Heart Failure · China2RecruitingDec 31, 202640
NCT05885854Myocardial Ischemia · China2CompletedMar 4, 202351
NCT05136391Coronary Artery Disease · China1CompletedAug 27, 202110

How it is read

Names in the registry

  • “XTR003”, 2 entries
  • “Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging”, 1 entry

Codes read as this program: XTR003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.